Cadrenal Therapeutics, Inc. Common Stock (CVKD) Stock Price

CVKDStock
$1.09−92.12%52W
Market Cap$3.38M
P/E—
PEG Ratio—
Div yield—
Beta1.90

CVKD Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-87.15%
Price vs S&P 500 (4W)1.33%
VGM Score26.06

CVKD Earnings Surprise History

QuarterReport dateEPS estimateEPS actualSurprise
Q2 2026-$0.95-$1.14-20.00%(-$0.19)
Q1 2026-$1.57-$1.04+33.97%(+$0.53)
Q4 2025-$1.21-$1.41-16.53%(-$0.20)
Q3 2025-$1.55-$1.31+15.48%(+$0.24)
Q2 2025-$1.77-$1.87-5.35%(-$0.10)

CVKD Analyst Recommendations

Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.13
4.13
4.13
4.13

Industry Peers — Pharmaceuticals(574)

SymbolValue ScoreGrowth ScoreMomentum ScoreP/S Ratio (TTM)Revenue Growth TTM (YoY)Gross Margin (TTM)EPS Growth (5Y)Price
CVKDCadrenal Therapeutics, Inc. Common Stock
——D————$1.09
LLYEli Lilly & Co.DBA14.9x49.6%83.4%27.6%$1257.03
JNJJohnson & JohnsonDCB6.2x7.8%67.7%14.9%$255.56
ABBVABBVIE INC.DCA7.8x10.4%72.8%-2.9%$285.42
MRKMerck & Co., Inc.DCA5.4x4.6%77.3%21.2%$145.95
NVSNovartis AGCCB4.9x3.3%75.0%15.3%$150.62
AZNAstraZeneca PLCCBB4.3x8.6%81.3%21.9%$165.41
ABTAbbott LaboratoriesCCB3.9x8.1%56.8%8.2%$104.89
NVONovo-Nordisk A/SBCC3.5x5.6%80.7%20.7%$38.83
PFEPfizer Inc.CDA2.6x-0.2%74.7%-3.5%$29.58
VRTXVertex Pharmaceuticals IncDCB10.1x10.2%86.0%8.3%$499.74

About Cadrenal Therapeutics, Inc. Common Stock

Cadrenal Therapeutics is developing tecarfarin, a late-stage novel oral anticoagulant designed to address unmet needs in treating rare cardiovascular conditions requiring chronic anticoagulation therapy. The reversible blood thinner is intended to prevent heart attacks, strokes, and clot-related mortality in patients with specific cardiovascular indications.